Sugi Predict

Sugi Predict / Targets / FSCN1

FSCN1

Fascin · Q16658 · FSCN1 on Sugi Atlas →

5,132 patent compounds predicted against FSCN1, 3,101 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2243133 SCHEMBL2243133 0.68 7/20
SCHEMBL1938471 SCHEMBL1938471 0.46 5/20
SCHEMBL3843880 SCHEMBL3843880 0.50 4/20
SCHEMBL2778910 SCHEMBL2778910 0.49 4/20
SCHEMBL2780397 SCHEMBL2780397 0.48 4/20
SCHEMBL2777007 SCHEMBL2777007 0.47 4/20
SCHEMBL3421426 SCHEMBL3421426 0.47 4/20
SCHEMBL3921773 SCHEMBL3921773 0.45 4/20
SCHEMBL2317430 SCHEMBL2317430 0.61 3/20
SCHEMBL692310 SCHEMBL692310 0.54 3/20
SCHEMBL2781467 SCHEMBL2781467 0.48 3/20
SCHEMBL2312640 SCHEMBL2312640 0.48 3/20
SCHEMBL2315711 SCHEMBL2315711 0.48 3/20
SCHEMBL3087107 SCHEMBL3087107 0.48 3/20
SCHEMBL2778927 SCHEMBL2778927 0.48 3/20
SCHEMBL367960 SCHEMBL367960 0.46 3/20
SCHEMBL357618 SCHEMBL357618 0.45 3/20
SCHEMBL2781253 SCHEMBL2781253 0.45 3/20
SCHEMBL3602541 SCHEMBL3602541 0.42 3/20
SCHEMBL1083204 SCHEMBL1083204 0.41 3/20

Clinical trials — most relevant to FSCN1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration PHASE2COMPLETED
Hormone Therapy With or Without Definitive Radiotherapy in Metastatic Prostate Cancer PHASE2UNKNOWN
68Ga-PMD22 PET/CT Examination Targeting CLDN18.2 EARLY_PHASE1UNKNOWN
Molecular Analysis of Patients With Neuromuscular Disease nanRECRUITING
Autologous Stem/Stromal Cells in Neurological Disorders and Disease nanUNKNOWN
Genetic Markers for Focal Segmental Glomerulosclerosis nanCOMPLETED
Genetic Analysis of Fraser Syndrome and Fryns Syndrome nanCOMPLETED
Predicting Postoperative Delirium Using EEG, Genetics and Neurobiomarkers of Cerebral Injury nanCOMPLETED
Thoracic Aortic Dilatation Syndromes nanCOMPLETED
3 Year Follow up on ANO5 Patients nanACTIVE_NOT_RECRUITING
Effect of Cerefolin®/CerefolinNAC® on Biomarker Measurements nanCOMPLETED
Neuroimaging Biomarkers of Prognosis in Motor Functional Neurological Disorders nanCOMPLETED
Stereo Photogrammetry Imaging in Normal Volunteers and Patients With Head and Facial Malformations nanCOMPLETED
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients nanRECRUITING
Application of Linkage Analysis in the Identification of Novel Hereditary Factors in Familial Aneurysms nanACTIVE_NOT_RECRUITING
Parkinson's Families Project nanRECRUITING
Significance of Cortactin Expression in Colorectal Adenocarcinomas nanCOMPLETED
The Effect of Aging on Value Based Decision-making nanCOMPLETED
Genetic Studies of Strabismus, Congenital Cranial Dysinnervation Disorders (CCDDs), and Their Associated Anomalies nanRECRUITING
Gait in Rare Diseases nanCOMPLETED
Biomarker Research in Inherited Movement Disorders nanRECRUITING
Hereditary Tubulointerstitial Nephritis nanCOMPLETED
Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers nanCOMPLETED
Observational Cohort Study of Dysferlinopathy in China nanCOMPLETED
Genetic Characterization of Parkinson's Disease nanCOMPLETED
Clinical Outcome Study for Dysferlinopathy nanUNKNOWN
Biomarker Levels as A Predictor of Concussion Severity OUTcomes (BlacOut) nanCOMPLETED
Effect of Eccentric Exercise on Musculus Triceps Surae Muscle Architecture, Muscle Strength, and Performance nanCOMPLETED
Gene Mutations and Rescue in Human Congenital Diaphragmatic Hernia nanUNKNOWN
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a FSCN1 binder may also engage these)

ProteinNameSimilarity
Q61553 — 1.000 Q61553 →
P85845 — 1.000 P85845 →
O18728 — 0.946 O18728 →
Q91837 — 0.939 Q91837 →
O14926 — 0.933 O14926 →
Q32M02 — 0.927 Q32M02 →
P11716 — 0.924 P11716 →
E9PZQ0 — 0.924 E9PZQ0 →
P16960 — 0.922 P16960 →
RYR1 Ryanodine receptor 1 0.922 landscape →
F1LMY4 — 0.920 F1LMY4 →
A2AGL3 — 0.919 A2AGL3 →
Q9TS33 — 0.919 Q9TS33 →
Q15413 — 0.917 Q15413 →
B0LPN4 — 0.911 B0LPN4 →
RYR2 Ryanodine receptor 2 0.910 landscape →
P30957 — 0.908 P30957 →
RCC2 Protein RCC2 0.904 landscape →
E9Q401 — 0.904 E9Q401 →
O70277 — 0.904 O70277 →
O75382 — 0.903 O75382 →
D2XV59 — 0.901 D2XV59 →
FRG1 Protein FRG1 0.901 landscape →
Q9ESN6 — 0.901 Q9ESN6 →
Q52KW8 — 0.901 Q52KW8 →
CSDE1 Cold shock domain-containing protein E1 0.900 landscape →
D3ZQG6 — 0.900 D3ZQG6 →
Q5RCZ7 — 0.900 Q5RCZ7 →
Q5ZIT8 — 0.899 Q5ZIT8 →
Q8BK67 — 0.899 Q8BK67 →